ERBB2 and breast cancer: We evaluated the effect of dual inhibition of AURKA and PAK1 on the proliferation of 5 luminal (MCF7, ZR75, T47D, BT474, MDA-MB-361), 4 hormone receptor negative (HR-) human epidermal growth factor receptor 2 positive (HER2 +) (HCC1954, HCC1419, HCC1569, SKBR3), and 4 triple negative (TNBC) (MDA-MB-157, MDA-MB-468, MDA-MB-231, HCC1806) breast cancer cell lines (Fig. 1, S1).